Pulmonx Q2 2024 GAAP EPS $(0.39) Beats $(0.44) Estimate, Sales $20.783M Beat $20.134M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pulmonx (NASDAQ:LUNG) reported Q2 2024 GAAP EPS of $(0.39), beating the $(0.44) estimate. Sales were $20.783M, surpassing the $20.134M estimate and marking a 20.87% increase from the same period last year.
July 31, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulmonx (NASDAQ:LUNG) reported better-than-expected Q2 2024 results with GAAP EPS of $(0.39) beating the $(0.44) estimate and sales of $20.783M surpassing the $20.134M estimate. Sales increased by 20.87% YoY.
Pulmonx's better-than-expected earnings and revenue growth indicate strong performance, likely leading to positive short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100